Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604825 · ClinicalTrials.gov registry record · Phase 2
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
A Phase 2 study of Menopausal and Female Climacteric States, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 356
- Enrollment target
- 20
- Study locations
NCT00604825 is a Phase 2 study of Menopausal and Female Climacteric States that has completed, run by GlaxoSmithKline. The registered enrollment target is 356 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT00604825, a Phase 2 study of Menopausal and Female Climacteric States, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 356 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
Conditions Studied
Interventions
- DRUG Other: Placebo
- DRUG GSK232802
- DRUG PREMARIN
Study Locations (20)
Florida
- GSK Investigational Site - Crystal River
- GSK Investigational Site - Fort Myers
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Miami
- GSK Investigational Site - Pinellas Park
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Glendale
- GSK Investigational Site - Scottsdale
- GSK Investigational Site - Tucson
Colorado
- GSK Investigational Site - Aurora
- GSK Investigational Site - Boulder
- GSK Investigational Site - Denver
- GSK Investigational Site - Wheat Ridge
California
- GSK Investigational Site - Poway
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Savannah
District of Columbia
- GSK Investigational Site - Washington D.C.
Kansas
- GSK Investigational Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2007-07-17 |
| Est. Completion | 2008-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604825
The ClinicalTrials.gov registry entry for NCT00604825 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Menopausal and Female Climacteric States appearing as the primary indexed condition, and to 3 interventions - of which Other: Placebo is the first listed.
NCT00604825 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00604825 about?
NCT00604825 is a clinical study titled "Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)". The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
What is the current status of trial NCT00604825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 356 participants. The study started on 2007-07-17. Estimated completion is 2008-07-23.
What conditions does trial NCT00604825 study?
This clinical trial studies the following conditions: Menopausal and Female Climacteric States.
What interventions are being tested in trial NCT00604825?
The interventions under investigation include: Other: Placebo (DRUG), GSK232802 (DRUG), PREMARIN (DRUG).
Who is sponsoring clinical trial NCT00604825?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00604825 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.